Aleva Neurotherapeutics SA

Aleva Neurotherapeutics SA is a Swiss medical technology company focused on developing and commercializing advanced Deep Brain Stimulation (DBS) systems for neurological disorders, including Parkinson’s disease and Essential Tremor. The company originated as a spin-off from the Swiss Federal Institute of Technology (EPFL) and has pioneered Directional Deep Brain Stimulation technology, which offers more precise brain stimulation with fewer side effects. The flagship product, the directSTIM™ system, is a comprehensive directional DBS solution designed to enhance patient outcomes by targeting specific brain areas. Aleva holds a robust intellectual property portfolio with 13 patent families and 90 granted patents related to DBS technologies. The company operates as a commercial-stage entity, having obtained CE marking for directSTIM™ and collaborates with leading neurological clinics across Europe. Aleva aims to expand its global market presence by partnering with neurologists and neurosurgeons, all while ensuring high-quality standards through its Swiss-based manufacturing. The mission of Aleva is to improve the lives of patients by providing personalized support and advancing DBS technology.

• Employees 2
• Founded 2013
• Annual Revenue $2500000
• Total Funding $44583634